renin–angiotensin system inhibitors + mineralocorticoid receptor antagonists

A combination therapy comprising **renin–angiotensin system (RAS) inhibitors** (including ACE inhibitors, angiotensin receptor blockers, or renin inhibitors) together with **mineralocorticoid receptor antagonists** (such as spironolactone, eplerenone, or finerenone). This regimen aims to achieve more comprehensive inhibition of the renin–angiotensin–aldosterone pathway, which regulates blood pressure, fluid volume, and electrolyte balance. RAS inhibitors reduce vasoconstriction, decrease aldosterone synthesis, and lower blood pressure, while mineralocorticoid receptor antagonists block aldosterone’s effects in the kidney, leading to additional reductions in sodium retention and myocardial fibrosis. The combination is investigated mainly in proteinuric chronic kidney disease and heart failure for additional organ protection and reduction of albuminuria, though benefits must be weighed against increased risks including hyperkalemia, hypotension, and renal impairment. These agents are not co-formulated, but used as distinct drugs in combination therapy[1][3][9][11].

Other names

renin–angiotensin system inhibitor plus mineralocorticoid receptor antagonist combinationdual RAAS blockade with mineralocorticoid antagonist